• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: ZIMMER / SEIKAGAKU CORPORATION, TAKAHAGI PLANT GEL ONE 30MG/3ML SYR; ACID, HYALURONIC, INTRAARTICULAR

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

ZIMMER / SEIKAGAKU CORPORATION, TAKAHAGI PLANT GEL ONE 30MG/3ML SYR; ACID, HYALURONIC, INTRAARTICULAR Back to Search Results
Device Problem Manufacturing, Packaging or Shipping Problem (2975)
Patient Problem Pain (1994)
Event Type  Injury  
Event Description
Pt reported that due to mdo mistake of sending rx somewhere else she was in the hosp in pain because she has been without medication.Arxwp has not dispensed but pt is established on medication.(b)(6).
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
GEL ONE 30MG/3ML SYR
Type of Device
ACID, HYALURONIC, INTRAARTICULAR
Manufacturer (Section D)
ZIMMER / SEIKAGAKU CORPORATION, TAKAHAGI PLANT
MDR Report Key12834955
MDR Text Key281029446
Report NumberMW5105404
Device Sequence Number1
Product Code MOZ
UDI-Device Identifier87541030091
UDI-Public87541030091
Combination Product (y/n)N
Reporter Country CodeUS
Number of Events Reported1
Summary Report (Y/N)N
Report Source Voluntary
Reporter Occupation Other Health Care Professional
Type of Report Initial
Report Date 11/12/2021
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Initial Date Manufacturer Received Not provided
Initial Date FDA Received11/17/2021
Patient Sequence Number1
Treatment
BOTOX; UBRELVY
Patient Outcome(s) Hospitalization;
Patient SexFemale
-
-